India's Zydus Cadila partners on drug-resistant infections research
Indian pharma company Zydus Cadila has joined forces with a government research organization to identify new drug candidates for treatment of drug-resistant infections.
The partnership is with the Council of Scientific and Industrial Research (CSIR)- Institute of Microbial Technology (IMTECH), a premier microbial institute under the aegis of the Ministry of Science and Technology.
The agreement between CSIR-IMTECH and Zydus will see scientists from both organizations working closely together on microbiology and genomics to identify new lead candidate asnovel anti-tuberculosis compounds. For this project, scientists at IMTECH will utilize their expertise and scientific knowledge in microbiology while Zydus Cadila will provide its expertise in medicinal chemistry and pharmaceutical drug development with an aim to develop new drug combinations against drug-resistant pathogens which causes severe diseases in India and across the world.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze